Contract terms
GTx-104 (nimodipine formulation) monthly WAC at launch? · v1 (current)
Market metadata
Market
gtx-104-nimodipine-formulation-monthly-wac-at-launch-dju94
Market ID
697b0f23b3eef31151c967b6
Rules version
v1
Rules published
Jan 29, 2026, 07:41 AM
Opens
Jan 13, 2026, 02:05 PM
Locks
May 23, 2026, 11:59 PM
Resolve-by
—
Measurement
WAC per course
Price range
$45,000–$50,000
Outcomes
This is a price-range bucket. YES resolves if the price is $45,000–$50,000; otherwise the outcome is NO. If the market is voided, stakes are refunded.
Resolution rules
Resolves YES if the initial U.S. wholesale acquisition cost (WAC) at launch for GTx-104 (nimodipine formulation) is ≥ $5,000/course, using the first publicly available WAC from a sponsor price announcement or a pricing compendium (e.g., Red Book / Medi-Span).
If GTx-104 (nimodipine formulation) does not have an FDA approval for Aneurysmal subarachnoid hemorrhage (aSAH) on or before 2026-05-23, resolves NO.
Reference: https://www.globenewswire.com/news-release/2025/08/27/3139943/0/en/Grace-Therapeutics-Announces-U-S-Food-and-Drug-Administration-Acceptance-for-Review-of-New-Drug-Application-for-GTx-104.html
Range: $45,000-$50,000.
Resolution procedure
Probiful admins resolve markets using the criteria above. If multiple sources disagree, admins follow the source hierarchy described in the resolution rules (if present).
Lock time: May 23, 2026, 11:59 PM. For “by date” markets, the phrase “on or before” is interpreted as inclusive of the calendar date shown in the contract.
If the market cannot be fairly resolved (e.g., no authoritative sources), it may be voided and stakes refunded.
Sources referenced
Accessed: Mar 26, 2026. This page is a snapshot of rules version v1.